The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CD62L Antibody Market Research Report 2024
Synopsis
CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells.
Global CD62L Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD62L Antibody market research.
Key companies engaged in the CD62L Antibody industry include Thermo Fisher Scientific, Leinco Technologies, Bio-Rad, BD Biosciences, Proteintech Group, RayBiotech, Abcam, GeneTex and LifeSpan BioSciences, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of CD62L Antibody were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole CD62L Antibody market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CD62L Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Thermo Fisher Scientific
Leinco Technologies
Bio-Rad
BD Biosciences
Proteintech Group
RayBiotech
Abcam
GeneTex
LifeSpan BioSciences
BioLegend
Antigenix America
NSJ Bioreagents
ichorbio
Miltenyi Biotec
Cell Sciences
Abbexa
Bio X Cell
Tonbo Biosciences
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CD62L Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells.
Global CD62L Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD62L Antibody market research.
Key companies engaged in the CD62L Antibody industry include Thermo Fisher Scientific, Leinco Technologies, Bio-Rad, BD Biosciences, Proteintech Group, RayBiotech, Abcam, GeneTex and LifeSpan BioSciences, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of CD62L Antibody were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole CD62L Antibody market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CD62L Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Thermo Fisher Scientific
Leinco Technologies
Bio-Rad
BD Biosciences
Proteintech Group
RayBiotech
Abcam
GeneTex
LifeSpan BioSciences
BioLegend
Antigenix America
NSJ Bioreagents
ichorbio
Miltenyi Biotec
Cell Sciences
Abbexa
Bio X Cell
Tonbo Biosciences
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CD62L Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD62L Antibody Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal
1.2.3 Polyclonal
1.3 Market by Application
1.3.1 Global CD62L Antibody Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Immunochemistry (IHC)
1.3.3 Immunofluorescence (IF)
1.3.4 Immunoprecipitation (IP)
1.3.5 Western Blot (WB)
1.3.6 ELISA
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CD62L Antibody Market Perspective (2018-2029)
2.2 CD62L Antibody Growth Trends by Region
2.2.1 Global CD62L Antibody Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CD62L Antibody Historic Market Size by Region (2018-2023)
2.2.3 CD62L Antibody Forecasted Market Size by Region (2024-2029)
2.3 CD62L Antibody Market Dynamics
2.3.1 CD62L Antibody Industry Trends
2.3.2 CD62L Antibody Market Drivers
2.3.3 CD62L Antibody Market Challenges
2.3.4 CD62L Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CD62L Antibody Players by Revenue
3.1.1 Global Top CD62L Antibody Players by Revenue (2018-2023)
3.1.2 Global CD62L Antibody Revenue Market Share by Players (2018-2023)
3.2 Global CD62L Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CD62L Antibody Revenue
3.4 Global CD62L Antibody Market Concentration Ratio
3.4.1 Global CD62L Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD62L Antibody Revenue in 2022
3.5 CD62L Antibody Key Players Head office and Area Served
3.6 Key Players CD62L Antibody Product Solution and Service
3.7 Date of Enter into CD62L Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CD62L Antibody Breakdown Data by Type
4.1 Global CD62L Antibody Historic Market Size by Type (2018-2023)
4.2 Global CD62L Antibody Forecasted Market Size by Type (2024-2029)
5 CD62L Antibody Breakdown Data by Application
5.1 Global CD62L Antibody Historic Market Size by Application (2018-2023)
5.2 Global CD62L Antibody Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CD62L Antibody Market Size (2018-2029)
6.2 North America CD62L Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CD62L Antibody Market Size by Country (2018-2023)
6.4 North America CD62L Antibody Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CD62L Antibody Market Size (2018-2029)
7.2 Europe CD62L Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CD62L Antibody Market Size by Country (2018-2023)
7.4 Europe CD62L Antibody Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CD62L Antibody Market Size (2018-2029)
8.2 Asia-Pacific CD62L Antibody Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CD62L Antibody Market Size by Region (2018-2023)
8.4 Asia-Pacific CD62L Antibody Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CD62L Antibody Market Size (2018-2029)
9.2 Latin America CD62L Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CD62L Antibody Market Size by Country (2018-2023)
9.4 Latin America CD62L Antibody Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CD62L Antibody Market Size (2018-2029)
10.2 Middle East & Africa CD62L Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CD62L Antibody Market Size by Country (2018-2023)
10.4 Middle East & Africa CD62L Antibody Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Detail
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific CD62L Antibody Introduction
11.1.4 Thermo Fisher Scientific Revenue in CD62L Antibody Business (2018-2023)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Leinco Technologies
11.2.1 Leinco Technologies Company Detail
11.2.2 Leinco Technologies Business Overview
11.2.3 Leinco Technologies CD62L Antibody Introduction
11.2.4 Leinco Technologies Revenue in CD62L Antibody Business (2018-2023)
11.2.5 Leinco Technologies Recent Development
11.3 Bio-Rad
11.3.1 Bio-Rad Company Detail
11.3.2 Bio-Rad Business Overview
11.3.3 Bio-Rad CD62L Antibody Introduction
11.3.4 Bio-Rad Revenue in CD62L Antibody Business (2018-2023)
11.3.5 Bio-Rad Recent Development
11.4 BD Biosciences
11.4.1 BD Biosciences Company Detail
11.4.2 BD Biosciences Business Overview
11.4.3 BD Biosciences CD62L Antibody Introduction
11.4.4 BD Biosciences Revenue in CD62L Antibody Business (2018-2023)
11.4.5 BD Biosciences Recent Development
11.5 Proteintech Group
11.5.1 Proteintech Group Company Detail
11.5.2 Proteintech Group Business Overview
11.5.3 Proteintech Group CD62L Antibody Introduction
11.5.4 Proteintech Group Revenue in CD62L Antibody Business (2018-2023)
11.5.5 Proteintech Group Recent Development
11.6 RayBiotech
11.6.1 RayBiotech Company Detail
11.6.2 RayBiotech Business Overview
11.6.3 RayBiotech CD62L Antibody Introduction
11.6.4 RayBiotech Revenue in CD62L Antibody Business (2018-2023)
11.6.5 RayBiotech Recent Development
11.7 Abcam
11.7.1 Abcam Company Detail
11.7.2 Abcam Business Overview
11.7.3 Abcam CD62L Antibody Introduction
11.7.4 Abcam Revenue in CD62L Antibody Business (2018-2023)
11.7.5 Abcam Recent Development
11.8 GeneTex
11.8.1 GeneTex Company Detail
11.8.2 GeneTex Business Overview
11.8.3 GeneTex CD62L Antibody Introduction
11.8.4 GeneTex Revenue in CD62L Antibody Business (2018-2023)
11.8.5 GeneTex Recent Development
11.9 LifeSpan BioSciences
11.9.1 LifeSpan BioSciences Company Detail
11.9.2 LifeSpan BioSciences Business Overview
11.9.3 LifeSpan BioSciences CD62L Antibody Introduction
11.9.4 LifeSpan BioSciences Revenue in CD62L Antibody Business (2018-2023)
11.9.5 LifeSpan BioSciences Recent Development
11.10 BioLegend
11.10.1 BioLegend Company Detail
11.10.2 BioLegend Business Overview
11.10.3 BioLegend CD62L Antibody Introduction
11.10.4 BioLegend Revenue in CD62L Antibody Business (2018-2023)
11.10.5 BioLegend Recent Development
11.11 Antigenix America
11.11.1 Antigenix America Company Detail
11.11.2 Antigenix America Business Overview
11.11.3 Antigenix America CD62L Antibody Introduction
11.11.4 Antigenix America Revenue in CD62L Antibody Business (2018-2023)
11.11.5 Antigenix America Recent Development
11.12 NSJ Bioreagents
11.12.1 NSJ Bioreagents Company Detail
11.12.2 NSJ Bioreagents Business Overview
11.12.3 NSJ Bioreagents CD62L Antibody Introduction
11.12.4 NSJ Bioreagents Revenue in CD62L Antibody Business (2018-2023)
11.12.5 NSJ Bioreagents Recent Development
11.13 ichorbio
11.13.1 ichorbio Company Detail
11.13.2 ichorbio Business Overview
11.13.3 ichorbio CD62L Antibody Introduction
11.13.4 ichorbio Revenue in CD62L Antibody Business (2018-2023)
11.13.5 ichorbio Recent Development
11.14 Miltenyi Biotec
11.14.1 Miltenyi Biotec Company Detail
11.14.2 Miltenyi Biotec Business Overview
11.14.3 Miltenyi Biotec CD62L Antibody Introduction
11.14.4 Miltenyi Biotec Revenue in CD62L Antibody Business (2018-2023)
11.14.5 Miltenyi Biotec Recent Development
11.15 Cell Sciences
11.15.1 Cell Sciences Company Detail
11.15.2 Cell Sciences Business Overview
11.15.3 Cell Sciences CD62L Antibody Introduction
11.15.4 Cell Sciences Revenue in CD62L Antibody Business (2018-2023)
11.15.5 Cell Sciences Recent Development
11.16 Abbexa
11.16.1 Abbexa Company Detail
11.16.2 Abbexa Business Overview
11.16.3 Abbexa CD62L Antibody Introduction
11.16.4 Abbexa Revenue in CD62L Antibody Business (2018-2023)
11.16.5 Abbexa Recent Development
11.17 Bio X Cell
11.17.1 Bio X Cell Company Detail
11.17.2 Bio X Cell Business Overview
11.17.3 Bio X Cell CD62L Antibody Introduction
11.17.4 Bio X Cell Revenue in CD62L Antibody Business (2018-2023)
11.17.5 Bio X Cell Recent Development
11.18 Tonbo Biosciences
11.18.1 Tonbo Biosciences Company Detail
11.18.2 Tonbo Biosciences Business Overview
11.18.3 Tonbo Biosciences CD62L Antibody Introduction
11.18.4 Tonbo Biosciences Revenue in CD62L Antibody Business (2018-2023)
11.18.5 Tonbo Biosciences Recent Development
11.19 Biobyt
11.19.1 Biobyt Company Detail
11.19.2 Biobyt Business Overview
11.19.3 Biobyt CD62L Antibody Introduction
11.19.4 Biobyt Revenue in CD62L Antibody Business (2018-2023)
11.19.5 Biobyt Recent Development
11.20 Jingjie PTM BioLab
11.20.1 Jingjie PTM BioLab Company Detail
11.20.2 Jingjie PTM BioLab Business Overview
11.20.3 Jingjie PTM BioLab CD62L Antibody Introduction
11.20.4 Jingjie PTM BioLab Revenue in CD62L Antibody Business (2018-2023)
11.20.5 Jingjie PTM BioLab Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
